Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
Taysha Gene Therapies (Nasdaq: TSHA) will release first quarter 2026 financial results for the period ended March 31, 2026, and host a corporate update conference call and webcast on Wednesday, May 6, 2026 at 8:30 AM ET.
Rhea-AI Summary
Taysha Gene Therapies (Nasdaq: TSHA) will release first quarter 2026 financial results for the period ended March 31, 2026, and host a corporate update conference call and webcast on Wednesday, May 6, 2026 at 8:30 AM ET. Participants can access the live webcast via the company’s Events and Presentations page at ir.tayshagtx.com, and an archived replay will be available afterward.
Positive
- None.
Negative
- None.
Details
News Market Reaction – TSHA
On Apr 29, the day this news came out, TSHA closed 0.48% below the previous close.
Data tracked by StockTitan Argus for the Apr 29 session.
Key Figures
- Quarter end date
- March 31, 2026
- First quarter 2026 reporting period
- Earnings call date
- May 6, 2026
- Scheduled Q1 2026 results release and call
- Earnings call time
- 8:30 AM Eastern Time
- Start time for Q1 2026 webcast and conference call
Previous Conferences,earnings date Reports
-
Announced timing and access details for full-year 2025 earnings call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
adeno-associated virus medical
central nervous system medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2026, and host a corporate update conference call and webcast on Wednesday, May 6, 2026, at 8:30 AM Eastern Time.
Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha’s website at ir.tayshagtx.com. An archived replay of the webcast will be available on the Company’s website.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.